Overview

  • Product name
  • Description
    Rabbit polyclonal to RUNX2
  • Specificity
    This antibody is specific for RUNX2
  • Tested applications
    Suitable for: ELISA, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Chicken, Cow, Dog
  • Immunogen

    A region within synthetic peptide: RQKLDDSKPS LFSDRLSDLG RIPHPSMRVG VPPQNPRPSL NSAPSPFNPQ, corresponding to internal sequence amino acids 217-266 of Human RUNX2

  • Positive control
    • HepG2 cell lysate

Properties

Applications

Our Abpromise guarantee covers the use of ab48812 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA 1/312500.
WB Use a concentration of 1.25 µg/ml. Detects a band of approximately 80 kDa (predicted molecular weight: 56 kDa). Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.

Target

  • Function
    Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters (By similarity). Inhibits MYST4-dependent transcriptional activation.
  • Tissue specificity
    Specifically expressed in osteoblasts.
  • Involvement in disease
    Defects in RUNX2 are the cause of cleidocranial dysplasia (CLCD) [MIM:119600]; also known as cleidocranial dysostosis (CCD). CLCD is an autosomal dominant skeletal disorder with high penetrance and variable expressivity. It is due to defective endochondral and intramembranous bone formation. Typical features include hypoplasia/aplasia of clavicles, patent fontanelles, wormian bones (additional cranial plates caused by abnormal ossification of the calvaria), supernumerary teeth, short stature, and other skeletal changes. In some cases defects in RUNX2 are exclusively associated with dental anomalies.
  • Sequence similarities
    Contains 1 Runt domain.
  • Domain
    A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes and contains the phosphorylation sites.
  • Post-translational
    modifications
    Phosphorylated; probably by MAP kinases (MAPK) (By similarity). Isoform 3 is phosphorylated on Ser-340.
  • Cellular localization
    Nucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • Acute myeloid leukemia 3 protein antibody
    • Alpha subunit 1 antibody
    • AML3 antibody
    • CBF alpha 1 antibody
    • CBF-alpha-1 antibody
    • CBFA1 antibody
    • CCD antibody
    • CCD1 antibody
    • Cleidocranial dysplasia 1 antibody
    • Core binding factor antibody
    • Core binding factor runt domain alpha subunit 1 antibody
    • Core binding factor subunit alpha 1 antibody
    • Core-binding factor subunit alpha-1 antibody
    • MGC120022 antibody
    • MGC120023 antibody
    • Oncogene AML 3 antibody
    • Oncogene AML-3 antibody
    • OSF 2 antibody
    • OSF-2 antibody
    • OSF2 antibody
    • Osteoblast specific transcription factor 2 antibody
    • Osteoblast-specific transcription factor 2 antibody
    • OTTHUMP00000016533 antibody
    • PEA2 alpha A antibody
    • PEA2-alpha A antibody
    • PEA2aA antibody
    • PEBP2 alpha A antibody
    • PEBP2-alpha A antibody
    • PEBP2A1 antibody
    • PEBP2A2 antibody
    • PEBP2aA antibody
    • PEBP2aA1 antibody
    • Polyomavirus enhancer binding protein 2 alpha A subunit antibody
    • Polyomavirus enhancer-binding protein 2 alpha A subunit antibody
    • Runt domain antibody
    • Runt related transcription factor 2 antibody
    • Runt-related transcription factor 2 antibody
    • RUNX2 antibody
    • RUNX2_HUMAN antibody
    • SL3 3 enhancer factor 1 alpha A subunit antibody
    • SL3-3 enhancer factor 1 alpha A subunit antibody
    • SL3/AKV core binding factor alpha A subunit antibody
    • SL3/AKV core-binding factor alpha A subunit antibody
    see all

Anti-RUNX2 antibody images

  • Anti-RUNX2 antibody (ab48812) at 1.25 µg/ml + HepG2 cell lysate at 10 µg

    Secondary
    HRP conjugated anti-Rabbit IgG at 1/50000 dilution

    Predicted band size : 56 kDa
    Observed band size : 80 kDa (why is the actual band size different from the predicted?)

References for Anti-RUNX2 antibody (ab48812)

ab48812 has not yet been referenced specifically in any publications.

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Western blot
Sample
Human Cell lysate - whole cell (primary vascular smooth muscle cells)
Loading amount
25 µg
Specification
primary vascular smooth muscle cells
Treatment
3.6 mM Ca2+ for 5 days
Gel Running Conditions
Reduced Denaturing (10% gel)
Blocking step
5% milk + 2.5% BSA in PBS+0.1% Tween-20 as blocking agent for 2 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 23°C
Username

Leilani Beltran

Verified customer

Submitted Sep 09 2011

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up